

## Regimen list

| Regimen                                                                                                                                               | Status   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| - Hypersensitivity - As Required Medications - Version 3                                                                                              | Active   |
| (*riTUXImab), Cyclophosphamide, vinCRISTine and prednisoLONE (*R)-CVP) –21 days - Version 3                                                           | Active   |
| (*riTUXImab)-Gemcitabine Cyclophosphamide vinCRISTine and prednisoLONE (* R)- GCVP- 21 days (00737) - Version 2                                       | Active   |
| (MAP) Methotrexate (12000mg/m <sup>2</sup> ) DOXOrubicin (37.5mg/m <sup>2</sup> /day) and CISplatin (60mg/m <sup>2</sup> ) Adj (00463.2) - Version 2  | Active   |
| (MAP) Methotrexate (12000mg/m <sup>2</sup> ) DOXOrubicin (37.5mg/m <sup>2</sup> /day) and CISplatin (60mg/m <sup>2</sup> ) Nadj (00463.1) - Version 2 | Active   |
| 5-Fluorouracil (4 day) and mitoMYcin Chemoradiation (00451) - Version 6                                                                               | Active   |
| 5-Fluorouracil (5 day) and mitoMYcin Chemoradiation (00450) - Version 4                                                                               | Active   |
| 5-fluorouracil 225mg/m <sup>2</sup> /day and Radiotherapy (RT)-Continuous infusion (7 day) - Version 6                                                | Active   |
| 5-Fluorouracil and Folinic Acid Therapy-14 day Adj - Version 3                                                                                        | Active   |
| 5-Fluorouracil and Folinic Acid Therapy-14 day- Met - Version 2                                                                                       | Active   |
| 5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) - Version 2                                                                             | Active   |
| 5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC 50) (00269) - Version 2                                                                       | Inactive |
| Abiraterone 1000mg and Prednisolone 5mg - Version 2                                                                                                   | Active   |
| Abiraterone and Prednisolone (00103) - Version 5                                                                                                      | Active   |
| ABVD (00290) - Version 5                                                                                                                              | Active   |
| Acalabrutinib Monotherapy - Version 1                                                                                                                 | Active   |
| Afatinib Monotherapy (00221) - Version 3                                                                                                              | Active   |
| Aflibercept and FOLFIRI -14 day (00238) - Version 1                                                                                                   | Inactive |
| Alectinib Monotherapy - Version 1                                                                                                                     | Active   |
| Anastrozole Monotherapy Adj - Version 4                                                                                                               | Active   |
| Anastrozole Monotherapy LA/M - Version 3                                                                                                              | Active   |
| Apalutamide (00574) - Version 1                                                                                                                       | Active   |
| Atezolizumab 1200mg Monotherapy - Version 2                                                                                                           | Active   |
| Atezolizumab 1200mg, CARBOplatin (AUC 5) and Etoposide (Day 1 IV, Day 2 & 3 oral) (00689.2) - Version 1                                               | Active   |
| Atezolizumab 1200mg, CARBOplatin (AUC 5) and Etoposide 100mg/m <sup>2</sup> (00689.1) - Version 4                                                     | Active   |
| Atezolizumab 1680mg Monotherapy – 28 Day (00593) - Version 3                                                                                          | Active   |
| Atezolizumab 840mg Monotherapy – 14 Day (00592) - Version 1                                                                                           | Active   |
| Atezolizumab and nab-PACLitaxel (00688) - Version 5                                                                                                   | Active   |
| Avelumab Monotherapy - Version 3                                                                                                                      | Active   |
| Axitinib Monotherapy - Version 2                                                                                                                      | Active   |
| azaCITIDine 100mg/m <sup>2</sup> IV 5-day (00288.2) - Version 2                                                                                       | Active   |
| azaCITIDine 100mg/m <sup>2</sup> SC 5-day (00288.1) - Version 7                                                                                       | Active   |
| azaCITIDine 75mg/m <sup>2</sup> IV 5-2-2 (00287.2) - Version 2                                                                                        | Active   |
| azaCITIDine 75mg/m <sup>2</sup> SC 5-2-2 (00287.1) - Version 7                                                                                        | Active   |
| BEAM Autologous Transplant Conditioning Protocol - Version 2                                                                                          | Active   |
| Bendamustine Monotherapy - Version 2                                                                                                                  | Active   |
| Bevacizumab 10mg/kg - 14 days (00212) - Version 5                                                                                                     | Active   |
| Bevacizumab 10mg/kg and PACLitaxel 80mg/m <sup>2</sup> - Version 2                                                                                    | Active   |
| Bevacizumab 10mg/kg and PACLitaxel 80mg/m <sup>2</sup> (Day 1, 8, 15 and 22) (00769) - Version 1                                                      | Active   |
| Bevacizumab 10mg/kg and Pegylated liposomal DOXOrubicin (CAELYX®) 40mg/m <sup>2</sup> - Version 1                                                     | Active   |
| Bevacizumab 10mg/kg and Topotecan 4mg/m <sup>2</sup> - Version 1                                                                                      | Active   |
| Bevacizumab 15mg/kg - 21 days (00215) - Version 6                                                                                                     | Active   |
| Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m <sup>2</sup> (00766) - Version 1                                                      | Active   |
| Bevacizumab 15mg/kg, PACLitaxel 175mg/m <sup>2</sup> and CISplatin 50mg/m <sup>2</sup> (00799) - Version 1                                            | Inactive |
| Bevacizumab 5mg/kg -14 days - Version 2                                                                                                               | Inactive |
| Bevacizumab 5mg/kg and FOLFIRI – 14 days - Version 3                                                                                                  | Active   |
| Bevacizumab 5mg/kg and FOLFOXIRI - 14 days (00783) - Version 1                                                                                        | Active   |
| Bevacizumab 5mg/kg and Modified FOLFOX- 6 – 14 days (00446) - Version 4                                                                               | Active   |
| Bevacizumab 7.5mg/kg – 21 days (00214) - Version 5                                                                                                    | Active   |

## Regimen list

| Regimen                                                                                                                                                             | Status   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m <sup>2</sup> Therapy- 21 day (00623) - Version 3                                                                     | Active   |
| Bevacizumab 7.5mg/kg, CARBOplatin(AUC5) and PACLitaxel 175mg/m <sup>2</sup> (00620) - Version 3                                                                     | Active   |
| Bicalutamide - Version 2                                                                                                                                            | Active   |
| Bleomycin, Etoposide and CISplatin (BEP) - Version 2                                                                                                                | Active   |
| Bortezomib and Dexamethasone (00270) - Version 4                                                                                                                    | Active   |
| Bortezomib and Lenalidomide (RVD-Lite) Consolidation - Version 1                                                                                                    | Active   |
| Bortezomib Maintenance - 14 day - Version 3                                                                                                                         | Active   |
| Bortezomib, Lenalidomide and Dexamethasone (RVD) - 21 day - Version 3                                                                                               | Active   |
| Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day - Version 2                                                                                       | Active   |
| Bortezomib, Lenalidomide and Dexamethasone (RVD-Lite) Induction - Version 1                                                                                         | Active   |
| Bortezomib, Melphalan & Prednisolone - Version 2                                                                                                                    | Active   |
| Bortezomib, Thalidomide and Dexamethasone (VTD) Induction - Version 2                                                                                               | Active   |
| Bosutinib Monotherapy (00224) - Version 3                                                                                                                           | Inactive |
| Brentuximab vedotin and Bendamustine - Version 1                                                                                                                    | Active   |
| Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and prednisOLONE (CHP) (00801) - Version 1                                                                    | Inactive |
| Brentuximab vedotin and ESHAP (BRESHAP) - Version 1                                                                                                                 | Active   |
| Brentuximab vedotin and ICE - Version 3                                                                                                                             | Active   |
| Brentuximab vedotin Monotherapy (00234) - Version 4                                                                                                                 | Active   |
| Brigatinib - Version 3                                                                                                                                              | Active   |
| Busulfan,Cyclophosphamide – MAC – SIB - Version 2                                                                                                                   | Active   |
| Busulfan,Cyclophosphamide,ATG Grafalon® – MAC – Mismatched Sibling Donor - Version 2                                                                                | Active   |
| Busulfan,Cyclophosphamide,ATG Grafalon® – MAC – Mismatched Unrelated Donor - Version 2                                                                              | Active   |
| Busulfan,Cyclophosphamide–MAC–MUD - Version 2                                                                                                                       | Active   |
| Cabazitaxel and Prednisolone (00101) - Version 3                                                                                                                    | Active   |
| Cabozantinib - Version 3                                                                                                                                            | Active   |
| Capecitabine 825mg/m <sup>2</sup> and RT-7 day - Version 3                                                                                                          | Active   |
| Capecitabine and Oxaliplatin Therapy (XELOX) Adj (00321.1) - Version 6                                                                                              | Active   |
| Capecitabine and Oxaliplatin Therapy (XELOX) Met (00321.2) - Version 5                                                                                              | Active   |
| Capecitabine and RT – 7 day - Version 5                                                                                                                             | Active   |
| Capecitabine and Temozolomide (00505) - Version 3                                                                                                                   | Active   |
| Capecitabine Monotherapy Adj (00216.1) - Version 6                                                                                                                  | Active   |
| Capecitabine Monotherapy LA/M (00216.2) - Version 6                                                                                                                 | Active   |
| CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT) -5 weeks (00422) - Version 8                                         | Active   |
| CARBOplatin (AUC 2) Weekly with Radiotherapy (RT) (00419) - Version 8                                                                                               | Active   |
| CARBOplatin (AUC 3), Etoposide (50mg/m <sup>2</sup> ) and Thoracic Radiotherapy (TRT) -28 day (00561) - Version 3                                                   | Active   |
| CARBOplatin (AUC 5) + Etoposide (Day 1 IV, Day 2 & 3 oral) -21 day (00271.2) - Version 1                                                                            | Active   |
| CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m <sup>2</sup> /day – 28 day (00552) - Version 7                                                                      | Active   |
| CARBOplatin (AUC 6) and PACLitaxel 200mg/m <sup>2</sup> (00304) - Version 6                                                                                         | Active   |
| CARBOplatin (AUC1.5) Chemoradiation - 7 days - Version 6                                                                                                            | Active   |
| CARBOplatin (AUC5) and Etoposide 100mg/m <sup>2</sup> - 21 days (00271.1) - Version 14                                                                              | Active   |
| CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m <sup>2</sup> - Version 3                                                                                            | Active   |
| CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m <sup>2</sup> Adj - Version 2                                                                                        | Active   |
| CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m <sup>2</sup> followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy- Triple Negative Breast Cancer - Version 5 | Active   |
| CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour - Version 1                                                                              | Active   |
| CARBOplatin 70mg/m <sup>2</sup> and 5-Fluorouracil 600mg/m <sup>2</sup> with Radiotherapy - Version 2                                                               | Active   |
| CARBOplatin and Oral Etoposide - 21days (00319) - Version 7                                                                                                         | Active   |
| CARBOplatin and vinORElbine Therapy-21 Day (00614) - Version 3                                                                                                      | Active   |
| CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m <sup>2</sup> with Radiotherapy - Version 4                                                                             | Active   |

## Regimen list

| Regimen                                                                                                                                                             | Status   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| CARBOplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m <sup>2</sup> Therapy-28 day - Version 2                                                                | Active   |
| CARBOplatin AUC4 Monotherapy-21 days (00261.3) - Version 6                                                                                                          | Active   |
| CARBOplatin AUC4 Monotherapy-28 days (00251.3) - Version 6                                                                                                          | Active   |
| CARBOplatin AUC5 and PACLitaxel 175mg/m <sup>2</sup> Adj (00303.7) - Version 7                                                                                      | Active   |
| CARBOplatin AUC5 and PACLitaxel 175mg/m <sup>2</sup> Met (00303.8) - Version 6                                                                                      | Active   |
| CARBOplatin AUC5 Monotherapy-21 days (00261.2) - Version 6                                                                                                          | Active   |
| CARBOplatin AUC5 Monotherapy-28 days (00251.2) - Version 6                                                                                                          | Active   |
| CARBOplatin AUC6 and PACLitaxel 175mg/m <sup>2</sup> Adj (00303.5) - Version 6                                                                                      | Active   |
| CARBOplatin AUC6 and PACLitaxel 175mg/m <sup>2</sup> Met (00303.6) - Version 7                                                                                      | Active   |
| CARBOplatin AUC6 Monotherapy-21 days (00261.1) - Version 8                                                                                                          | Active   |
| CARBOplatin AUC6 Monotherapy-28 days (00251.1) - Version 8                                                                                                          | Active   |
| CARBOplatin AUC7 and PACLitaxel 175mg/m <sup>2</sup> Adj (00303.3) - Version 6                                                                                      | Active   |
| CARBOplatin AUC7 and PACLitaxel 175mg/m <sup>2</sup> Met (00303.4) - Version 6                                                                                      | Active   |
| CARBOplatin AUC7.5 and PACLitaxel 175mg/m <sup>2</sup> Adj (00303.1) - Version 8                                                                                    | Active   |
| CARBOplatin AUC7.5 and PACLitaxel 175mg/m <sup>2</sup> Met (00303.2) - Version 9                                                                                    | Active   |
| Carfilzomib (20/70mg/m <sup>2</sup> Once weekly) Dexamethasone (Kd) therapy - 28 day - Version 2                                                                    | Active   |
| Carfilzomib (27mg/m <sup>2</sup> twice weekly), Lenalidomide and Dexamethasone (KRd) - 28 day - Version 4                                                           | Active   |
| Carfilzomib (56mg/m <sup>2</sup> once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day - Version 2                                                     | Active   |
| Carfilzomib and Dexamethasone (Kd) - 28 day - Version 5                                                                                                             | Active   |
| Carmustine,Etoposide,Cytarabine,Melphalan,Alemtuzumab RIC-SIB/MUD - Version 2                                                                                       | Active   |
| Cemiplimab (00812) - Version 1                                                                                                                                      | Inactive |
| Ceritinib Monotherapy - Version 1                                                                                                                                   | Active   |
| Cetuximab – 14 days - Version 1                                                                                                                                     | Active   |
| Cetuximab - 7 day (12 weeks) (00207.1) - Version 6                                                                                                                  | Active   |
| Cetuximab - 7 day (8 weeks) (00207.2) - Version 6                                                                                                                   | Active   |
| Cetuximab (14 days) and FOLFIRI (14 days) - Version 2                                                                                                               | Active   |
| Cetuximab (14 days) and Irinotecan (14 days) - Version 3                                                                                                            | Active   |
| Cetuximab (7 days) and FOLFIRI (14 days) Therapy - Version 5                                                                                                        | Active   |
| Cetuximab (7 days) and Irinotecan (14 days) - Version 3                                                                                                             | Active   |
| Cetuximab (weekly), CARBOplatin AUC 5 and 5-Fluorouracil 1000mg/m <sup>2</sup> /day - 21 day cycle - Version 10                                                     | Active   |
| Cetuximab (weekly), CISplatin 100mg/m <sup>2</sup> and 5-Fluorouracil 1000mg/m <sup>2</sup> /day - 21 day cycle - Version 6                                         | Active   |
| Cetuximab and FOLFOX-6 (modified) - Version 1                                                                                                                       | Active   |
| CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and ONE dose gemtuzumab ozogamicin (for patients ≥1 year and >10kg and BSA ≥ 0.5m <sup>2</sup> ) - Version 2   | Inactive |
| CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and THREE dose gemtuzumab ozogamicin (for patients ≥1 year and >10kg and BSA ≥ 0.5m <sup>2</sup> ) - Version 3 | Inactive |
| CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and TWO dose Gemtuzumab Ozogamicin ( <1 year or ≤10kg or BSA <0.5m <sup>2</sup> ) - Version 2                  | Inactive |
| CHI AML MyeChild Course 2 - FLA IDA (for HR patients <1 year or ≤10kg or BSA <0.5m <sup>2</sup> ) - Version 2                                                       | Inactive |
| CHI AML MyeChild Course 2 – FLA IDA (for HR patients ≥1 year and >10kg and BSA ≥0.5m <sup>2</sup> ) - Version 2                                                     | Inactive |
| CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients <1 year or ≤10kg or BSA <0.5m <sup>2</sup> ) - Version 2                                  | Inactive |
| CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients ≥1 year and >10kg and BSA ≥0.5m <sup>2</sup> ) - Version 2                                | Inactive |
| CHI AML MyeChild Course 3 - FLA (for HR patients ≥1 year and >10kg and BSA ≥0.5m <sup>2</sup> ) - Version 1                                                         | Inactive |
| CHI AML MyeChild Course 3 - FLA (for HR patients <1 year or ≤10kg or BSA <0.5m <sup>2</sup> ) - Version 1                                                           | Inactive |
| CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients <1 year or ≤10kg or BSA <0.5m <sup>2</sup> ) - Version 1                                                | Inactive |
| CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients ≥1 year and >10kg and BSA ≥0.5m <sup>2</sup> ) - Version 1                                              | Inactive |
| CHI AML MyeChild Course 3 and 4 - FLA (for SR patient ≥1 year and >10kg and BSA ≥0.5m <sup>2</sup> ) - Version 1                                                    | Inactive |

## Regimen list

| Regimen                                                                                                         | Status   |
|-----------------------------------------------------------------------------------------------------------------|----------|
| CHI AML MyeChild Course 3 and 4 - FLA (for SR patients <1 year or ≤10kg or BSA <0.5m²) - Version 2              | Inactive |
| CHI AML Myechild Course 3 and 4 - HD Cytarabine (for SR patients <1 year or ≤10kg or BSA <0.5m²) - Version 2    | Inactive |
| CHI AML Myechild Course 3 and 4 - HD Cytarabine (for SR patients ≥1 year and >10kg and BSA ≥0.5m²) - Version 1  | Inactive |
| CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients <1 year or ≤10kg or BSA <0.5m²) - Version 1   | Inactive |
| CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients ≥1 year and >10kg and BSA ≥0.5m²) - Version 1 | Inactive |
| CHI ES IE/VC Consolidation Euro Ewing 2012 - Version 1                                                          | Active   |
| CHI ES VDC/IE Induction Euro Ewing 2012 - Version 3                                                             | Active   |
| CHI HBL PHITT Group B (CISplatin with STS Anhydrous) for patients ≥10kg - Version 1                             | Active   |
| CHI HBL PHITT Group C C5VD with STS Anhydrous for patients ≥10kg - Version 1                                    | Active   |
| CHI HBL PHITT Group C CDDP-M (CISplatin with STS Anhydrous) for patients ≥10kg - Version 1                      | Active   |
| CHI HBL PHITT Group C SIOPEL-3HR with Sodium Thiosulphate Anhydrous for patients ≥10kg - Version 1              | Active   |
| CHI HBL PHITT Group D Induction for patients ≥10kg - Version 3                                                  | Active   |
| CHI HBL PHITT Group D1 Consolidation CARBOplatin and DOXOrubicin (CD) for patients ≥10kg - Version 1            | Inactive |
| CHI HBL PHITT Group D2 Consolidation CD/CE for patients ≥10kg - Version 1                                       | Inactive |
| CHI HBL PHITT Group D2 Consolidation CD/VI for patients ≥10kg - Version 1                                       | Inactive |
| CHI HL COPDAC Consolidation (2 cycles) - Version 3                                                              | Active   |
| CHI HL COPDAC Consolidation (4 cycles) - Version 3                                                              | Active   |
| CHI HL DECOPDAC Consolidation (2 cycles) - Version 2                                                            | Active   |
| CHI HL DECOPDAC Consolidation (4 cycles) - Version 2                                                            | Active   |
| CHI HL OEPA Induction - Version 2                                                                               | Active   |
| CHI LCH IV Continuation Arm A for patients ≥10kg - Version 1                                                    | Active   |
| CHI LCH IV Continuation Arm B for patients ≥10kg - Version 1                                                    | Active   |
| CHI LCH IV Continuation Arm C for patients ≥10kg - Version 1                                                    | Active   |
| CHI LCH IV Continuation Arm D for patients ≥10kg - Version 1                                                    | Active   |
| CHI LCH IV Stratum 1 Initial course 1 (weekly vinBLASTine) for patients ≥10kg (CHI 1106.1) - Version 1          | Active   |
| CHI LCH IV Stratum 1 Initial course 2 (weekly vinBLASTine) for patients ≥10kg (CHI 1107.1) - Version 1          | Active   |
| CHI LGG Standard Consolidation (patients aged ≥1 year) - Version 2                                              | Active   |
| CHI LGG Standard Consolidation (patients aged 6months – 1 year) - Version 3                                     | Inactive |
| CHI LGG Standard Consolidation (patients aged less than 6months) - Version 3                                    | Inactive |
| CHI LGG Standard Induction (patients aged ≥1 year) - Version 2                                                  | Active   |
| CHI LGG Standard Induction (patients aged 6months – 1 year) - Version 3                                         | Active   |
| CHI LGG Standard Induction (patients aged less than 6months) - Version 3                                        | Inactive |
| CHI LGG weekly vinBLASTine (BSA <0.6m²) CHI1062.2 - Version 3                                                   | Active   |
| CHI LGG weekly vinBLASTine (BSA ≥0.6m²) CHI1062.1 - Version 3                                                   | Active   |
| CHI RMS IVA (9 cycles) for patients > 1 year and > 10kg - Version 1                                             | Inactive |
| CHI RMS VA (8 cycles) for patients >1year and >10kg - Version 1                                                 | Inactive |
| CHI UKALL 2019 Regimen A Maintenance with IT Methotrexate (CHI1144.1) - Version 1                               | Active   |
| CHI UKALL 2019 Regimen B Maintenance with IT Methotrexate (CHI1145.1) - Version 1                               | Active   |
| CHI UKALL 2019 Regimen C Maintenance with IT Methotrexate (CHI1146.1) - Version 1                               | Active   |
| CHI WT Post Op HR-1 (loc) for patients ≥12kg (CCLG Clinical Management Guidelines) CHI1081.1 - Version 1        | Inactive |
| CHI WT Post Op HRm for patients ≥12kg (CCLG Clinical Management Guidelines). - Version 1                        | Inactive |
| Chlorambucil 10mg/m² - Version 2                                                                                | Active   |
| CHOEP – 21 days - Version 3                                                                                     | Active   |
| CISplatin (100mg/m²) with Radiotherapy (RT) - 21 day - Version 7                                                | Active   |

## Regimen list

| Regimen                                                                                                                                                                  | Status   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| CISplatin (40mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT) (5 cycles) (00385.1) - Version 9                                                                          | Active   |
| CISplatin (40mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT) (6 cycles) (00385.2) - Version 8                                                                          | Active   |
| CISplatin (50mg/m <sup>2</sup> ) and Etoposide (50mg/m <sup>2</sup> ) and Thoracic Radiotherapy (TRT) -28 day - Version 5                                                | Active   |
| CISplatin (50mg/m <sup>2</sup> ) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m <sup>2</sup> ) – Endometrial Cancer - Version 4                  | Active   |
| CISplatin (75mg/m <sup>2</sup> ) + Etoposide - 21 day (00280.2) - Version 8                                                                                              | Active   |
| CISplatin (75mg/m <sup>2</sup> ) + Etoposide (100mg/m <sup>2</sup> ) +Thoracic Radiotherapy (TRT) -21 day (00279.1) - Version 7                                          | Active   |
| CISplatin (75mg/m <sup>2</sup> ) + Etoposide (Day 1 IV, Day 2 & 3 Oral) -21 day (00280.1) - Version 2                                                                    | Active   |
| CISplatin 75mg/m <sup>2</sup> and 5-Fluorouracil Chemoradiation - Herskovic Regimen - Version 5                                                                          | Active   |
| CISplatin and 5-Fluorouracil- 28 day cycle - Version 2                                                                                                                   | Active   |
| CISplatin and Capecitabine Adjuvant Chemoradiation (00473) - Version 2                                                                                                   | Active   |
| CISplatin, 5-Fluorouracil and Radiation Therapy - Version 2                                                                                                              | Active   |
| CISplatin, Methotrexate and vinBLASTine (CMV) - Version 2                                                                                                                | Active   |
| Cladribine 0.14mg/kg Day 1 to 5 Therapy - Version 3                                                                                                                      | Active   |
| Cladribine 0.14mg/kg Weekly - Version 4                                                                                                                                  | Active   |
| Cladribine 5 day and ritUXimab - Version 2                                                                                                                               | Active   |
| Cladribine Weekly and ritUXimab - Version 2                                                                                                                              | Active   |
| COMP- Pembrolizumab in combination with chemotherapy (Nadj) and Pembrolizumab monotherapy (Adj) locally advanced or early stage TNBC high risk of recurrence - Version 1 | Active   |
| Crizotinib Monotherapy (00243) - Version 5                                                                                                                               | Active   |
| CT- CPD-DARA CTRIAL-IE 19-17 - Version 2                                                                                                                                 | Active   |
| Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Adj (00381.1) - Version 6                                                                             | Active   |
| Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Met (00381.2) - Version 4                                                                             | Active   |
| Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 day Adj (00378.1) - Version 3                                                                             | Active   |
| Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Met (00378.2) - Version 3                                                                             | Inactive |
| Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Met - Version 2                                                                                            | Active   |
| Cyclophosphamide 1500mg/m <sup>2</sup> For Stem Cell Mobilisation (00795) - Version 1                                                                                    | Active   |
| Cyclophosphamide 2000mg/m <sup>2</sup> for Stem Cell mobilisation (high dose cyclophosphamide) (00438) - Version 2                                                       | Active   |
| Cyclophosphamide(Oral) Methotrexate and 5-Fluorouracil (CMF) Adj - Version 2                                                                                             | Active   |
| Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day - Version 3                                                                                               | Active   |
| Cyclophosphamide, DOXOrubicin and CISplatin Therapy – 21 Day - Version 2                                                                                                 | Active   |
| Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisoLONE (CHOP) Therapy– 21 days (00307.1) - Version 2                                                                | Active   |
| Cyclophosphamide,Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor - Version 2                                                                                   | Active   |
| Cyclophosphamide,Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor - Version 1                                                                                 | Active   |
| Cyclophosphamide,Total Body Irradiation (TBI)–MAC–MUD - Version 2                                                                                                        | Active   |
| Cyclophosphamide,Total Body Irradiation (TBI)–MAC–SIB - Version 2                                                                                                        | Active   |
| DA (50/100) (3+8) Course 2 Induction (AML-17) (00360) - Version 5                                                                                                        | Active   |
| DA(60/100) 3+10: Course 1 Induction (AML-17) (00359) - Version 6                                                                                                         | Active   |
| Dabrafenib Monotherapy (00237) - Version 3                                                                                                                               | Active   |
| Dacarbazine - Version 1                                                                                                                                                  | Active   |
| Dacarbazine (1.2g/m <sup>2</sup> ) -21 day - Version 3                                                                                                                   | Active   |
| Dacomitinib Monotherapy - Version 1                                                                                                                                      | Active   |
| DACTINomycin (00247) - Version 2                                                                                                                                         | Active   |
| Daratumumab (IV), Bortezomib and Dexamethasone Therapy (00560) - Version 3                                                                                               | Active   |
| Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy - Version 1                                                                                       | Active   |

## Regimen list

| Regimen                                                                                                                                        | Status   |
|------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Daratumumab (SC 1800mg), Bortezomib and Dexamethasone - Version 1                                                                              | Active   |
| Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and Dexamethasone Consolidation Therapy - Version 2                                    | Active   |
| Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and Dexamethasone Induction Therapy - Version 1                                        | Active   |
| Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation (00755) - Version 1                                                  | Active   |
| Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy - Version 2                                                      | Active   |
| Daratumumab Monotherapy - Version 4                                                                                                            | Active   |
| Daratumumab SC Monotherapy - Version 3                                                                                                         | Active   |
| Darolutamide - Version 1                                                                                                                       | Active   |
| Decitabine Monotherapy (00231) - Version 3                                                                                                     | Active   |
| Degarelix-28 day - Version 3                                                                                                                   | Active   |
| Denosumab 120mg - Version 1                                                                                                                    | Active   |
| Dexamethasone, ritUXimab and Cyclophosphamide (DRC) - Version 2                                                                                | Active   |
| DOCEtaxel /Cyclophosphamide (TC)-21 day (00250) - Version 6                                                                                    | Active   |
| DOCEtaxel 75mg/m <sup>2</sup> –Prednisolone Combination - Version 2                                                                            | Active   |
| DOCEtaxel Monotherapy 100mg/m <sup>2</sup> - 21 day (00202) - Version 4                                                                        | Active   |
| DOCEtaxel Monotherapy 50mg/m <sup>2</sup> – 14 day cycle - Version 5                                                                           | Active   |
| DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle (00203) - Version 3                                                                   | Active   |
| DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®) (TCHP) - Version 1                                                                 | Active   |
| DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days (00258) - Version 7                                                                     | Active   |
| DOCEtaxel, CARBOplatin, Trastuzumab (SC) and Pertuzumab (TCH(SC) P) – 21 days - Version 2                                                      | Active   |
| DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) – 21 days - Version 2                                                                | Active   |
| DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy - Version 3                                                         | Active   |
| DOCEtaxel,CISplatin, 5-Fluorouracil and Radiotherapy - Version 3                                                                               | Active   |
| Dose Adjusted R-EPOCH Dose level 1 (initial dose) (00355.1) - Version 5                                                                        | Active   |
| Dose Adjusted R-EPOCH Dose level 2 (00355.4) - Version 1                                                                                       | Active   |
| Dose Adjusted R-EPOCH Dose level 3 (00355.5) - Version 1                                                                                       | Active   |
| Dose Adjusted R-EPOCH Dose level Minus 1 (-1) (00355.3) - Version 1                                                                            | Inactive |
| Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day (DD AC-T) (00278) - Version 9                  | Active   |
| Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) - Version 2 | Active   |
| Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day (DD AC-T) (00485) - Version 7                    | Active   |
| Dose Dense DOXOrubicin, Cyclophosphamide (AC60/600) 14 day followed by weekly PACLitaxel and Trastuzumab Therapy (DD AC-TH) - Version 3        | Active   |
| DOXOrubicin (25mg/m <sup>2</sup> /day) and CISplatin (100mg/m <sup>2</sup> )-21 day cycle-NADJ - Version 2                                     | Active   |
| DOXOrubicin (60) and Ifosfamide - Version 2                                                                                                    | Active   |
| DOXOrubicin (60mg/m <sup>2</sup> ) - Version 3                                                                                                 | Active   |
| DOXOrubicin (75) and Ifosfamide NAdj - Version 3                                                                                               | Active   |
| DOXOrubicin 50mg/m <sup>2</sup> /DOCEtaxel 75mg/m <sup>2</sup> (AT 50/75)-21 day cycle - Version 2                                             | Active   |
| DOXOrubicin 75mg/m <sup>2</sup> Monotherapy - Version 2                                                                                        | Active   |
| DOXOrubicin, and Cyclophosphamide (AC 60/600) - 21 day (00252) - Version 3                                                                     | Active   |
| DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) - Version 2                 | Active   |
| DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) (00260) - Version 4                         | Active   |
| Durvalumab Monotherapy 10mg/Kg-14 Day - Version 2                                                                                              | Active   |
| Durvalumab Monotherapy 1500mg – 28 Day - Version 2                                                                                             | Active   |
| EMA/CO Therapy (Etoposide, Methotrexate, DACTINomycin, Cyclophosphamide, vinCRISline) (00248) - Version 3                                      | Active   |
| EMA/EP Therapy (Etoposide Methotrexate DACTINomycin/Etoposide CISplatin) - Version 4                                                           | Active   |
| Encorafenib and Binimetinib - Version 2                                                                                                        | Inactive |

## Regimen list

| Regimen                                                                                                       | Status |
|---------------------------------------------------------------------------------------------------------------|--------|
| Entrectinib - Version 1                                                                                       | Active |
| Enzalutamide Monotherapy (00233) - Version 4                                                                  | Active |
| EpiRUBicin 75 + Cyclophosphamide (EC75) -21 day - Version 2                                                   | Active |
| EpiRUBicin 90 + Cyclophosphamide (EC90)-21 day - Version 2                                                    | Active |
| epiRUBicin, CISplatin and 5-Fluorouracil (ECF) - ADJ -21 day (00240.2) - Version 3                            | Active |
| epiRUBicin, CISplatin and 5-Fluorouracil (ECF) -21 day LA/M (00240.1) - Version 3                             | Active |
| epiRUBicin, CISplatin and Capecitabine (ECX) Adj (00380.2) - Version 1                                        | Active |
| epiRUBicin, CISplatin and Capecitabine (ECX) LA/M (00380.3) - Version 2                                       | Active |
| epiRUBicin, CISplatin and Capecitabine (ECX) NAdj (00380.1) - Version 2                                       | Active |
| EpiRUBicin, Oxaliplatin and 5-Fluorouracil (EOF)- 21 day - Version 3                                          | Active |
| epiRUBicin, Oxaliplatin and Capecitabine (EOX) -21 day (00239) - Version 5                                    | Active |
| eriBULin Monotherapy (00228) - Version 4                                                                      | Active |
| Erlotinib Monotherapy (00219) - Version 4                                                                     | Active |
| Escalated Dose BEACOPP 21 day (00354) - Version 3                                                             | Active |
| ESHAP (00394.1) - Version 3                                                                                   | Active |
| Etoposide and CISplatin 20mg/m <sup>2</sup> (EP) 5 day - Version 4                                            | Active |
| Everolimus and Exemestane - Version 2                                                                         | Active |
| Everolimus Monotherapy (00320) - Version 2                                                                    | Active |
| Exemestane Monotherapy Adj - Version 2                                                                        | Active |
| Exemestane Monotherapy Met - Version 2                                                                        | Active |
| Fedratinib Therapy (00788) - Version 1                                                                        | Active |
| FLAG Therapy (00363) - Version 4                                                                              | Active |
| FLAG: Ida 8mg/m <sup>2</sup> (00362) - Version 7                                                              | Active |
| FLOT -14 day NAdj (00344.1) - Version 5                                                                       | Active |
| FLOT-14 day Adj (00344.2) - Version 5                                                                         | Active |
| FLOX - Version 2                                                                                              | Active |
| Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®) - Version 1            | Active |
| Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL - Version 3         | Active |
| Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL - Version 2              | Active |
| Fludarabine, Cyclophosphamide and ritUXimab (FC IV+R) (00241) - Version 5                                     | Active |
| Fludarabine, Cyclophosphamide and ritUXimab (FC Oral +R) - Version 2                                          | Active |
| Fludarabine, Busulfan, ATG Grafalon® – RIC – MUD - Version 1                                                  | Active |
| Fludarabine, Busulfan, ATG Grafalon® – RIC –SIB - Version 2                                                   | Active |
| Fludarabine, Melphalan, Alemtuzumab-RIC-MUD - Version 1                                                       | Active |
| Fludarabine, Melphalan, Alemtuzumab-RIC-SIB - Version 1                                                       | Active |
| FOLFIRI 14 day (00227) - Version 7                                                                            | Active |
| FOLFIRINOX (00329) - Version 4                                                                                | Active |
| FOLFIRINOX- Rectal Carcinoma - Version 2                                                                      | Active |
| FOLFOX-4 14 day Adj (00210.1) - Version 6                                                                     | Active |
| FOLFOX-4 14 day Met - Version 4                                                                               | Active |
| FOLFOX-6 Modified 14 day Met (00209.2) - Version 10                                                           | Active |
| FOLFOX-6 Modified 14 day Adj (00209.1) - Version 11                                                           | Active |
| FOLFOX-6 Modified Chemoradiation-14 day - Version 4                                                           | Active |
| FOLFOXIRI - Version 4                                                                                         | Active |
| Fulvestrant (00361) - Version 2                                                                               | Active |
| Gefitinib Monotherapy (00220) - Version 2                                                                     | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) and RT - Version 3                                                       | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) and Capecitabine (650mg/m <sup>2</sup> )-21 day (00384) - Version 2      | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CARBOplatin (AUC 4) - 21 day (00306) - Version 7                     | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CARBOplatin (AUC 5)- 21 day - Version 5                              | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (25mg/m <sup>2</sup> ) - 21 day - Version 3                | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (35mg/m <sup>2</sup> ) - 21 day - Version 2                | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) - 21 day - Version 2                | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (70mg/m <sup>2</sup> ) Therapy- 28 day (00282) - Version 2 | Active |

## Regimen list

| Regimen                                                                                                | Status |
|--------------------------------------------------------------------------------------------------------|--------|
| Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 28 day Adj (00284.1) - Version 5                    | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 28 day Met (00284.2) - Version 5                    | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ) Monotherapy - 56 day (00283) - Version 4                          | Active |
| Gemcitabine (1000mg/m <sup>2</sup> ), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg - 21 day - Version 5 | Active |
| Gemcitabine (1250mg/m <sup>2</sup> ) and CISplatin (75mg/m <sup>2</sup> )- 21 day (00281) - Version 3  | Active |
| Gemcitabine (1250mg/m <sup>2</sup> ) and CISplatin (80mg/m <sup>2</sup> ) - 21 day - Version 2         | Active |
| Gemcitabine (1250mg/m <sup>2</sup> ) Monotherapy - 21 day - Version 2                                  | Active |
| Gemcitabine (400mg/m <sup>2</sup> ) and RT - Version 3                                                 | Active |
| Gemcitabine (600mg/m <sup>2</sup> ) and RT-7 day - Version 3                                           | Active |
| Gemcitabine and CARBOplatin (AUC2) - 21 days - Version 3                                               | Active |
| Gemcitabine and DOCEtaxel - 21 day - Version 3                                                         | Active |
| Gemtuzumab ozogamicin, DAUNOrubicin and cytarabine (AML induction) - Version 1                         | Active |
| Goserelin 10.8mg-12 weeks - Version 3                                                                  | Active |
| Goserelin 3.6mg-28 day - Version 2                                                                     | Active |
| High Dose Cytarabine - Version 3                                                                       | Active |
| High Dose Cytarabine Consolidation Therapy (post R-MPV) - 28 day (00666) - Version 1                   | Active |
| High Dose Melphalan Conditioning for Autologous Stem Cell Transplant - Version 2                       | Active |
| High dose Methotrexate, high dose Cytarabine, riTUXimab and Thiotepa (MATRix) (00508) - Version 2      | Active |
| Ibrutinib Therapy CLL / Waldenström's macroglobulinaemia (00296) - Version 4                           | Active |
| Ibrutinib Therapy Mantle Cell Lymphoma - Version 3                                                     | Active |
| ICE (Ifosfamide, CARBOplatin and Etoposide) (00397.1) - Version 4                                      | Active |
| Idelalisib Monotherapy (00291) - Version 2                                                             | Active |
| Imatinib - GIST Adj - Version 3                                                                        | Active |
| Imatinib - GIST Met - Version 2                                                                        | Active |
| Inotuzumab ozogamicin Monotherapy - Version 2                                                          | Active |
| Intermediate Dose Cytarabine - Version 5                                                               | Active |
| Intrathecal Methotrexate for CNS prophylaxis in GTN - Version 2                                        | Active |
| Intravenous Vinorelbine Monotherapy - 21 day (00232) - Version 4                                       | Active |
| Ipilimumab Monotherapy (00105) - Version 4                                                             | Active |
| Irinotecan 150mg/m <sup>2</sup> Monotherapy - 28 day - Version 1                                       | Active |
| Irinotecan Monotherapy - 21 days (00213) - Version 4                                                   | Active |
| Ixazomib, Lenalidomide and Dexamethasone- 28 day - Version 2                                           | Active |
| Lapatinib and Capecitabine - Version 2                                                                 | Active |
| Larotrectinib Monotherapy- Adult - Version 1                                                           | Active |
| LEAM Autologous Transplant Conditioning (00468) - Version 4                                            | Active |
| Lenalidomide 25mg and Dexamethasone- 28 day (00218) - Version 2                                        | Active |
| Lenalidomide Maintenance Therapy (RVD-Lite) - Version 1                                                | Active |
| Lenvatinib – HCC ≥ 60 kg - Version 1                                                                   | Active |
| Lenvatinib -DTC Therapy (00295) - Version 4                                                            | Active |
| Lenvatinib- HCC- patients < 60kg - Version 1                                                           | Active |
| Letrozole Monotherapy Adj - Version 4                                                                  | Active |
| Letrozole Monotherapy Met - Version 4                                                                  | Active |
| Letrozole Monotherapy NAdj - Version 3                                                                 | Active |
| Leuprorelin 11.25mg-12 weeks - Version 3                                                               | Active |
| Leuprorelin 22.5mg-12 weeks - Version 3                                                                | Active |
| Leuprorelin 3.75mg-28 days - Version 2                                                                 | Active |
| Leuprorelin 30mg-24 weeks - Version 2                                                                  | Active |
| Leuprorelin 45mg-24 week - Version 3                                                                   | Active |
| Leuprorelin 7.5mg-28 day - Version 2                                                                   | Active |
| Lomustine and Bevacizumab 5mg/kg (00742) - Version 1                                                   | Active |
| Lorlatinib - Version 1                                                                                 | Active |
| Methotrexate 8 day Charing Cross Regimen (00246) - Version 2                                           | Active |
| Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -14 Days - Version 2                           | Active |
| Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Adj - Version 2                       | Active |



## Regimen list

| Regimen                                                                                     | Status   |
|---------------------------------------------------------------------------------------------|----------|
| Methotrexate,vinBLASStine, DOXOrubicin, CISplatin (MVAC) -28 Days Met - Version 2           | Active   |
| Methotrexate,vinBLASStine, DOXOrubicin, CISplatin (MVAC) -28 Days NAdj - Version 2          | Active   |
| Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy - Version 1                     | Active   |
| Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy (00683) - Version 3      | Active   |
| Midostaurin Maintenance - Version 1                                                         | Active   |
| Mifamurtide - Version 1                                                                     | Inactive |
| mitoMYcin and Capecitabine Chemoradiation (00727) - Version 2                               | Active   |
| Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone – Weekly Therapy - Version 3 | Active   |
| Modified FOLFIRINOX - Version 2                                                             | Active   |
| nab-PACLitaxel and Gemcitabine - 28 day (00256) - Version 4                                 | Active   |
| nab-PACLitaxel Monotherapy– 21 day (00230) - Version 2                                      | Active   |
| nab-PACLitaxel Weekly Monotherapy–28 day (00736) - Version 2                                | Active   |
| Neoadjuvant DOCETaxel, CISplatin,5-Fluorouracil and Chemoradiation and Surgery - Version 4  | Active   |
| Neratinib - Version 1                                                                       | Active   |
| Nintedanib - Version 1                                                                      | Active   |
| Niraparib Monotherapy for patients ≥77kg (00571.1) - Version 1                              | Active   |
| Nivolumab 1mg/kg Ipilimumab 3mg/kg - Version 3                                              | Active   |
| Nivolumab 3mg/kg with Ipilimumab 1mg/kg - Version 2                                         | Active   |
| Nivolumab Monotherapy 240mg - 14 days (00483.1) - Version 7                                 | Active   |
| Nivolumab Monotherapy 240mg - 14 days Adj (26 cycles)(00483.2) - Version 5                  | Active   |
| Nivolumab Monotherapy 480mg-28 days (00484.1) - Version 6                                   | Active   |
| Nivolumab Monotherapy 480mg-28 days Adj (13 cycles) (00484.2) - Version 5                   | Active   |
| Nivolumab, ipilimumab, CARBOplatin and PACLitaxel - Version 2                               | Active   |
| Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin (AUC 5) (00713.1) - Version 2             | Active   |
| Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin (AUC 6) (00713.2) - Version 2             | Active   |
| Nivolumab, ipilimumab, PEMEtrexed and CISplatin (00714) - Version 1                         | Active   |
| Nordic Therapy - Version 1                                                                  | Active   |
| Obinutuzumab and Bendamustine-28 day cycle - Version 4                                      | Active   |
| Obinutuzumab and Chlorambucil - Version 2                                                   | Active   |
| Obinutuzumab and CHOP-21 day - Version 3                                                    | Active   |
| Obinutuzumab Cyclophosphamide vinCRISStine and prednisoLONE (O-CVP)-21 days - Version 3     | Active   |
| Obinutuzumab Maintenance Therapy-56 day (00425) - Version 4                                 | Active   |
| Olaparib (Capsule) Monotherapy - Version 2                                                  | Active   |
| Olaparib (Tablet) Monotherapy (00588) - Version 1                                           | Inactive |
| Oral Etoposide - Version 3                                                                  | Active   |
| Oral Vinorelbine Monotherapy-7 days - Version 4                                             | Active   |
| Osimertinib Monotherapy - Version 1                                                         | Active   |
| PACLitaxel (80) and Trastuzumab-7 day (12 weeks) - Version 3                                | Active   |
| PACLitaxel 80mg/m <sup>2</sup> Day 1, 8 and 15 Monotherapy-28 Day (00621) - Version 3       | Active   |
| PACLitaxel Monotherapy 80mg/m <sup>2</sup> Day 1, 8, 15 and 22 – 28 Day (00226) - Version 9 | Active   |
| PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) - Version 2              | Active   |
| Palbociclib-28 day - Version 3                                                              | Active   |
| Panitumumab 6mg/kg (00225) - Version 5                                                      | Active   |
| Panitumumab 6mg/kg and FOLFIRI -14 day - Version 4                                          | Active   |
| Panitumumab 6mg/kg and Modified FOLFOX-6 – 14 day (00447) - Version 5                       | Active   |
| PAZOPanib - Version 1                                                                       | Active   |
| Pegylated Liposomal DOXOrubicin 20 mg/m <sup>2</sup> (CAELYX)® 21 days - Version 3          | Active   |
| Pegylated Liposomal DOXOrubicin 50mg/m <sup>2</sup> (CAELYX) 28 days (00205) - Version 5    | Active   |
| Pembrolizumab 200mg and Axitinib (00583) - Version 1                                        | Active   |

## Regimen list

| Regimen                                                                                               | Status   |
|-------------------------------------------------------------------------------------------------------|----------|
| Pembrolizumab 200mg Monotherapy (00455.1) - Version 10                                                | Active   |
| Pembrolizumab 200mg Monotherapy Adj (18 cycles) (00455.2) - Version 7                                 | Active   |
| Pembrolizumab 400mg Monotherapy (00558.1) - Version 10                                                | Active   |
| Pembrolizumab 400mg Monotherapy Adj (9 cycles) (00558.2) - Version 7                                  | Active   |
| Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy (00705) - Version 2                     | Active   |
| Pembrolizumab, CISplatin and 5-Fluorouracil (00706) - Version 2                                       | Active   |
| Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) (00579) - Version 6                                 | Active   |
| Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) (00568) - Version 4                                 | Active   |
| Pembrolizumab, PEMEtrexed and CISplatin (00569) - Version 2                                           | Active   |
| PEMEtrexed and CARBOplatin (00318) - Version 6                                                        | Active   |
| PEMEtrexed and CISplatin (00317) - Version 3                                                          | Active   |
| PEMEtrexed Monotherapy (00222) - Version 4                                                            | Active   |
| Pertuzumab and Trastuzumab (Continuation) - Version 2                                                 | Active   |
| Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel - 21 day cycle (00796) - Version 2                 | Active   |
| Pertuzumab and Trastuzumab (Phesgo®) Maintenance Therapy - Version 1                                  | Active   |
| Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle Adj (00350.2) - Version 4                  | Active   |
| Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle NAdj (00350.1) - Version 4                 | Active   |
| Pertuzumab and Trastuzumab and DOCEtaxel Therapy - 21 day (00204) - Version 5                         | Active   |
| Pertuzumab Trastuzumab (Phesgo®) and vinORELbine (00798) - Version 1                                  | Inactive |
| Pertuzumab Trastuzumab and Vinorelbine - Version 3                                                    | Active   |
| Pertuzumab Trastuzumab and Weekly PACLitaxel - 21 day cycle - Version 4                               | Active   |
| Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel - 21 day - Version 1                           | Active   |
| Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin (TRAIN-2) - Version 1                    | Active   |
| Pixantrone Therapy - Version 3                                                                        | Active   |
| Polatuzumab Vedotin, Bendamustine and riTUXimab - Version 2                                           | Active   |
| Pomalidomide and Dexamethasone (00245) - Version 3                                                    | Active   |
| PONATinib - Version 1                                                                                 | Active   |
| Procarbazine Lomustine and vinCRISTine (PCV) - Version 4                                              | Active   |
| Procarbazine, Lomustine and vinCRISTine (PCV) Therapy – 56 days - Version 1                           | Active   |
| QUASAR (Modified) Fluorouracil (370mg/m <sup>2</sup> ) and Folinic Acid (50mg) Weekly Adj - Version 5 | Active   |
| QUASAR (Modified) Fluorouracil (370mg/m <sup>2</sup> ) and Folinic Acid (50mg) Weekly Met - Version 4 | Active   |
| R- miniCHOP - 21 days (00436) - Version 4                                                             | Active   |
| R-CEOP – 21 days - Version 3                                                                          | Active   |
| R-CHOP - 21 days (00307.2) - Version 6                                                                | Active   |
| R-CHOP-14 days - Version 7                                                                            | Active   |
| R-CODOX-M (Patients >65 years) - Version 2                                                            | Active   |
| R-CODOX-M (Patients ≤65yrs) - Version 2                                                               | Active   |
| R-DHAP - Version 2                                                                                    | Active   |
| Regorafenib Monotherapy (00244) - Version 4                                                           | Active   |
| R-ESHAP (00394.2) - Version 5                                                                         | Active   |
| R-Gemcitabine (1000mg/m <sup>2</sup> ) Oxaliplatin - 14 day - Version 2                               | Active   |
| Ribociclib-28 day - Version 1                                                                         | Active   |
| R-ICE (riTUXimab), Ifosfamide, CARBOplatin and Etoposide) - Version 6                                 | Active   |
| riTUXimab (S/C 1400mg) Maintenance - 56 day - Version 3                                               | Active   |
| riTUXimab (S/C 1400mg) Maintenance - 84 day - Version 3                                               | Active   |
| RiTUXimab 375 mg/m <sup>2</sup> - 7 day - Version 2                                                   | Active   |
| riTUXimab 375 mg/m <sup>2</sup> Combination Therapy-21 day - Version 3                                | Active   |
| RiTUXimab 375 mg/m <sup>2</sup> Maintenance Therapy- 56 day - Version 3                               | Active   |
| RiTUXimab 375mg/m <sup>2</sup> - Follicular Lymphoma (every 2 months) - Version 2                     | Inactive |
| RiTUXimab 375mg/m <sup>2</sup> - Follicular Lymphoma (every 3 months) - Version 2                     | Inactive |
| RiTUXimab 375mg/m <sup>2</sup> - Follicular Lymphoma (once weekly for four weeks) - Version 2         | Inactive |
| RiTUXimab 375mg/m <sup>2</sup> Maintenance-84 day - Version 3                                         | Active   |

## Regimen list

| Regimen                                                                                                            | Status   |
|--------------------------------------------------------------------------------------------------------------------|----------|
| RiTUXimab and Bendamustine - Version 3                                                                             | Active   |
| riTUXimab S/C, (R-CHOP) Therapy– 21 Days - Version 1                                                               | Active   |
| riTUXimab** Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP) - Version 2                                       | Active   |
| riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction (00664) - Version 1              | Active   |
| riTUXimab-HyperCVAD (MCL) – Part A (00466) - Version 1                                                             | Active   |
| riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B (00467) - Version 1                        | Active   |
| R-IVAC (Patients >65 years) - Version 2                                                                            | Active   |
| R-IVAC (patients ≤ 65 years) - Version 2                                                                           | Active   |
| Roswell Park Modified (Fluorouracil 500mg/m <sup>2</sup> and Folinic Acid 50mg weekly x 6) Regimen Adj - Version 4 | Active   |
| Roswell Park Modified (Fluorouracil 500mg/m <sup>2</sup> and Folinic Acid 50mg weekly x 6) Regimen Met - Version 4 | Active   |
| Ruxolitinib Monotherapy (00229) - Version 3                                                                        | Active   |
| Siltuximab Monotherapy - Version 2                                                                                 | Active   |
| SMILE (NK or T-cell lymphoma) (00407) - Version 2                                                                  | Inactive |
| SORafenib - Version 2                                                                                              | Active   |
| SUNitinib 37.5mg - Version 1                                                                                       | Active   |
| SUNitinib 50mg - Version 1                                                                                         | Active   |
| SUNitinib 50mg Therapy (21 days) (00719) - Version 1                                                               | Active   |
| Talazoparib - Version 1                                                                                            | Active   |
| Tamoxifen Monotherapy Adj - Version 2                                                                              | Active   |
| Tamoxifen Monotherapy Met - Version 2                                                                              | Active   |
| Temozolomide Recurrent Therapy - Version 2                                                                         | Active   |
| Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Patients greater than 65 years - Version 2              | Active   |
| Temozolomide with Radiotherapy (RT) and Adjuvant Therapy (00334) - Version 2                                       | Active   |
| Temsirolimus Monotherapy - Version 3                                                                               | Active   |
| TESTING Regimen - Version 1                                                                                        | Active   |
| Tivozanib Therapy - Version 1                                                                                      | Inactive |
| Topotecan Monotherapy – 5 day - Version 3                                                                          | Active   |
| Topotecan Monotherapy – Weekly - Version 3                                                                         | Active   |
| Topotecan Oral Monotherapy - Version 2                                                                             | Active   |
| Trabectedin and Pegylated Liposomal DOXOrubicin (PLD) - Version 3                                                  | Active   |
| Trabectedin Monotherapy - Version 2                                                                                | Active   |
| Trametinib and Dabrafenib Adj - Version 1                                                                          | Active   |
| Trametinib and Dabrafenib Met - Version 2                                                                          | Active   |
| Transcription only. See original prescription. - Version 1                                                         | Active   |
| Trastuzumab (IV) Monotherapy - 21 days Adj (00200.1) - Version 6                                                   | Active   |
| Trastuzumab (IV) Monotherapy - 7 days - Version 4                                                                  | Active   |
| Trastuzumab (IV) Monotherapy- 21 days Met (00200.2) - Version 6                                                    | Active   |
| Trastuzumab 5-Fluorouracil and CISplatin - 21 days - Version 4                                                     | Active   |
| Trastuzumab and FOLFOX-6 Modified - 14 day - Version 3                                                             | Active   |
| Trastuzumab Emtansine (Kadcyla®) - 21 days (00206) - Version 4                                                     | Active   |
| Trastuzumab Emtansine (Kadcyla®) Early Breast Cancer Therapy- 21 days (00659) - Version 2                          | Active   |
| Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer (00272) - Version 6                                    | Active   |
| Trastuzumab Subcutaneous 21 days - Early Breast Cancer (00285) - Version 6                                         | Active   |
| Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation - Version 2                                             | Active   |
| Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction - Version 2                                                 | Active   |
| Tretinoin (ATRA/IDArubicin (PETHEMA AIDA) Induction: High Risk (00366) - Version 2                                 | Active   |
| Triptorelin 11.25mg-12 weeks - Version 2                                                                           | Active   |
| Triptorelin 22.5mg-24 weeks - Version 2                                                                            | Active   |
| Triptorelin 3mg-28 day - Version 1                                                                                 | Active   |
| Two Day Etoposide CISplatin (EP) - Version 2                                                                       | Active   |
| Vandetanib Therapy (00242) - Version 3                                                                             | Active   |
| Vemurafenib Monotherapy (00102) - Version 4                                                                        | Active   |

## Regimen list

| Regimen                                                                                | Status |
|----------------------------------------------------------------------------------------|--------|
| Venetoclax and Obinutuzumab - Version 2                                                | Active |
| Venetoclax and ritUXimab Therapy - Version 1                                           | Active |
| Venetoclax Monotherapy - Version 2                                                     | Active |
| VinBLASTine and Methotrexate - Version 2                                               | Active |
| Vinorelbine 30 (Day 1,8,15) and CISplatin 80 (Day1) Therapy- 21 day - Version 2        | Active |
| Vinorelbine and CISplatin Therapy - 28 day - Version 2                                 | Active |
| Vismodegib Monotherapy (00236) - Version 3                                             | Active |
| Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation - Version 2              | Active |
| Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction - Version 1                  | Active |
| Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m <sup>2</sup> with Radiotherapy - Version 7 | Active |
| Zanubrutinib - Version 1                                                               | Active |
| Zoledronic Acid -28 days - Version 1                                                   | Active |
| Zoledronic Acid- 3 monthly - Version 2                                                 | Active |
| Zoledronic Acid- 6 monthly - Version 2                                                 | Active |
| Zoledronic Acid Monotherapy (00545) - Version 4                                        | Active |